




The relative strengths and weaknesses of Spyre Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spyre Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 152% points. The greatest weakness of Spyre Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 385%, being 141% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	66,424
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,965
Liabilities, Non-Current	132
Other Assets	40
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	4,836
Other Revenues	0
Property and Equipment	599
Research and Development	18,143
Selling, General and Administrative Expense	8,391

Output Variable	Value in 1000 USD
Assets	67,063
Liabilities	4,097
Expenses	26,534
Revenues	0
Stockholders Equity	62,966
Net Income	-21,698
Comprehensive Net Income	-21,700
BaseVar	51,266
ECR before Limited Liability	325%
Economic Capital Ratio	385%